Thalassemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Thalassemia – Drugs In Development, 2024 report and make more profitable business decisions.
Thalassemia is a group of inherited blood disorders that affect the body’s ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite, and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.
The Thalassemia drugs in development market research report provide comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thalassemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Thalassemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 75 molecules, with 68 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Thalassemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Thalassemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thalassemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abfero Pharmaceuticals IncAgios Pharmaceuticals Inc
Allife Medical Science and Technology Co Ltd
Ariya Bio
ASC Therapeutics Inc
Ascentage Pharma Group Inc
Austhera BioSciences Inc
Beam Therapeutics Inc
Bellicum Pharmaceuticals Inc
Biomac Lifesciences Pvt Ltd
BRL Medicine Inc
Cell Source Inc
Centre for Stem Cell Research
Cetya Therapeutics Inc
CHA Biotech Co Ltd
CorrectSequence Therapeutics Co Ltd
CRISPR Therapeutics AG
CSL Ltd
Disc Medicine Inc
EdiGene Inc
Editas Medicine Inc
Garuda Therapeutics Inc
Genmedicn Biopharma Ltd
Guangzhou Reforgene Medicine Co Ltd
Hangzhou Zede Pharmaceutical Technology Co Ltd
Imago BioSciences Inc
ImmuneCyte Inc
Intas Pharmaceuticals Ltd
Invenux LLC
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
Kanglin Biotech Hangzhou Co Ltd
Mabwell Therapeutics Inc
Merck & Co Inc
Merganser Biotech Inc
Mina Therapeutics Ltd
Monte Rosa Therapeutics Inc
Nanfang Hospital
Nanomedic Inc
Novartis AG
Novo Nordisk AS
Orchard Therapeutics Plc
Phoenicia Biosciences Inc
Prolong Pharmaceuticals LLC
Rallybio Corp
Rare Partners Srl
Regenacy Pharmaceuticals LLC
San Rocco Therapeutics LLC
Sana Biotechnology Inc
Shanghai BDgene Therapeutics Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Vitalgen BioPharma Co Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Hemogen Gene Biotechnology Co Ltd
Shenzhen Pregene Biopharma Co Ltd
Silence Therapeutics Plc
Suzhou GenAssist Therapeutics Co Ltd
Syros Pharmaceuticals Inc
TransThera Sciences (Nanjing) Inc
U.S. National Institutes of Health
University of Oxford
Vertex Pharmaceuticals Inc
Vifor Pharma Management Ltd
Weill Cornell Medical College
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Thalassemia reports